0:31:04 · Corey Kasimov, Evercore · Povetacicept label
How often did patients fall below the IgG threshold or need dose interruptions in RAINIER, and what does that imply for monitoring in the commercial povetacicept label, given a recent citizen petition?
Reshma Kewalramani said the petition was anonymous and FDA talks are proceeding normally, and that over 500 trial patients were measured every four weeks with no opportunistic infections and serious infections balanced with placebo. — Reshma Kewalramani
0:34:05 · Jessica Fai, JPMorgan · AMPLITUDE endpoint
What would count as a win in the AMPLITUDE interim analysis on proteinuria and eGFR?
A statistically significant eGFR slope difference versus placebo, since that is what the FDA accelerated approval agreement for inaxaplin is based on. — Reshma Kewalramani
0:35:43 · Salveen Richter, Goldman Sachs · Manufacturing, inaxaplin
How comfortable is Vertex with its povetacicept manufacturer, and why is it confident in separation from placebo at the 48-week inaxaplin interim?
Vertex has used the same manufacturer throughout and the FDA's manufacturing review is proceeding as expected, and proteinuria reductions in homogeneous kidney disease have been linked to eGFR gains in a rapidly progressive disease. — Reshma Kewalramani
0:39:29 · Jeff Meacham, Citibank · Povetacicept, DPN
How much will two-year eGFR data matter to povetacicept's competitive position, and what would a win look like in diabetic peripheral neuropathy?
Vertex will run to two-year eGFR because other regulators want it, and Duncan McKechnie said nephrologists already link proteinuria to eGFR; a neuropathy win is suzetrigine beating placebo. — Reshma Kewalramani, Duncan McKechnie
0:43:25 · Evan Seigerman, BMO Capital Markets · JOURNAVX gross-to-net
How will prescription growth bridge to reported JOURNAVX revenue as the patient support program rolls off?
Vertex is keeping the program on until mid-2027 because about 82% of managed lives are covered, after which gross to net should settle at 50 to 60% and revenue should grow in line. — Duncan McKechnie
0:45:48 · Brian Abrams, RBC Capital Markets · Launch uptake, ALYFTREK
How should initial povetacicept uptake balance enthusiasm against patients already on a class drug, and what is the trajectory for ALYFTREK conversion?
ALYFTREK growth is driven by new reimbursement agreements and rare-mutation indications, while for povetacicept there are about 163,000 untreated IgAN patients and Vertex will share launch metrics in early 2027. — Duncan McKechnie, Reshma Kewalramani
0:48:33 · Michael Wee, UBS · Inaxaplin endpoints
Does the eGFR benefit seen in IgAN imply a small eGFR delta could be significant for inaxaplin, and what did the Parasol group say about a proteinuria endpoint?
Parasol is interested in a proteinuria endpoint but the FDA agreement is on eGFR, and how proteinuria is lowered matters, which Vertex believes favors a drug targeting underlying cause. — Reshma Kewalramani
0:52:01 · Tazeen Amid, Bank of America · CF next-generation
How did VX-828 data compare with expectations, and where is the biggest remaining unmet need in CF?
The sweat chloride results covered expectations but Vertex will wait for the other two next-generation 3.0 correctors next year before choosing one, and remaining need is getting more patients below 30. — Reshma Kewalramani
0:55:01 · Akash Tawari, Jefferies · Two-year eGFR
Why commit to two-year eGFR data now, and how are placebo patients who start another drug handled statistically?
Vertex wants global filings and not all ex-U.S. regulators accept one-year eGFR, and the statistical analysis plan sets clear rules for dropouts and missing data. — Reshma Kewalramani
0:57:43 · Terrence Flynn, Morgan Stanley · AMPLIFIED cohort
Was the AMPLIFIED proteinuria reduction in the moderate-proteinuria cohort driven by a small FSGS subset?
No, because most patients in that cohort did not have FSGS. — Reshma Kewalramani
0:59:00 · Mohid Bansal, Wells Fargo · Manufacturing
Should investors worry about the use of continuous manufacturing for povetacicept and FDA involvement?
The FDA has been involved and has had the full manufacturing module since the filing at the end of March, and management feels good about the filing including manufacturing.